Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Feedback from the Sixth International AIDS Conference, San Francisco 1990.

× No keyword cloud information.

11 in total

1. Low prevalence of neurological and neuropsychological abnormalities in otherwise healthy HIV-1-infected individuals: results from the multicenter AIDS Cohort Study.

Authors: J C McArthur; B A Cohen; O A Selnes; A J Kumar; K Cooper; J H McArthur; G Soucy; D R Cornblath; J S Chmiel; M C Wang
Journal: Ann Neurol Date: 1989-11 Impact factor: 10.422

Review 2. Monitoring of lymphocyte subpopulation changes in the assessment of HIV infection.

Authors: A G Bird
Journal: Genitourin Med Date: 1990-06

3. A randomized controlled trial of a reduced daily dose of zidovudine in patients with the acquired immunodeficiency syndrome. The AIDS Clinical Trials Group.

Authors: M A Fischl; C B Parker; C Pettinelli; M Wulfsohn; M S Hirsch; A C Collier; D Antoniskis; M Ho; D D Richman; E Fuchs
Journal: N Engl J Med Date: 1990-10-11 Impact factor: 91.245

Review 4. Fluconazole, a new antifungal agent.

Authors: J N Galgiani
Journal: Ann Intern Med Date: 1990-08-01 Impact factor: 25.391

5. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy.

Authors: B A Larder; G Darby; D D Richman
Journal: Science Date: 1989-03-31 Impact factor: 47.728

6. HIV-1 infection: no evidence of cognitive decline during the asymptomatic stages. The Multicenter AIDS Cohort Study.

Authors: O A Selnes; E Miller; J McArthur; B Gordon; A Muñoz; K Sheridan; R Fox; A J Saah
Journal: Neurology Date: 1990-02 Impact factor: 9.910

7. Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT).

Authors: B A Larder; S D Kemp
Journal: Science Date: 1989-12-01 Impact factor: 47.728

8. A pilot study of low-dose zidovudine in human immunodeficiency virus infection.

Authors: A C Collier; S Bozzette; R W Coombs; D M Causey; D A Schoenfeld; S A Spector; C B Pettinelli; G Davies; D D Richman; J M Leedom
Journal: N Engl J Med Date: 1990-10-11 Impact factor: 91.245

9. The safety and efficacy of zidovudine (AZT) in the treatment of subjects with mildly symptomatic human immunodeficiency virus type 1 (HIV) infection. A double-blind, placebo-controlled trial. The AIDS Clinical Trials Group.

Authors: M A Fischl; D D Richman; N Hansen; A C Collier; J T Carey; M F Para; W D Hardy; R Dolin; W G Powderly; J D Allan
Journal: Ann Intern Med Date: 1990-05-15 Impact factor: 25.391

10. Zidovudine in asymptomatic human immunodeficiency virus infection. A controlled trial in persons with fewer than 500 CD4-positive cells per cubic millimeter. The AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases.

Authors: P A Volberding; S W Lagakos; M A Koch; C Pettinelli; M W Myers; D K Booth; H H Balfour; R C Reichman; J A Bartlett; M S Hirsch
Journal: N Engl J Med Date: 1990-04-05 Impact factor: 91.245